-
EP4291651
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP4291651
| EP4291651 - COMPOUNDS AND METHODS FOR REDUCING PLN EXPRESSION [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 17.11.2023 Database last updated on 28.03.2026 | |
| Former | The international publication has been made Status updated on 19.08.2022 | Most recent event Tooltip | 18.03.2026 | New entry: Fee payment for request for further processing | Applicant(s) | For all designated states Ionis Pharmaceuticals, Inc. 2855 Gazelle Court Carlsbad, CA 92010 / US | [2023/51] | Inventor(s) | 01 /
MULLICK, Adam Carlsbad, CA 92010 / US | 02 /
BUI, Huynh-Hoa Carlsbad, CA 92010 / US | 03 /
FREIER, Susan M. Carlsbad, CA 92010 / US | 04 /
YEH, Ting Yuan Carlsbad, CA 92010 / US | 05 /
KUBLI, Dieter Carlsbad, CA 92010 / US | [2023/51] | Representative(s) | AstraZeneca Intellectual Property Eastbrook House Shaftesbury Road Cambridge CB2 8BF / GB | [N/P] |
| Former [2023/51] | Carpmaels & Ransford LLP One Southampton Row London WC1B 5HA / GB | Application number, filing date | 22753363.5 | 10.02.2022 | [2023/51] | WO2022US16015 | Priority number, date | US202163148579P | 11.02.2021 Original published format: US 202163148579 P | [2023/51] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2022173976 | Date: | 18.08.2022 | Language: | EN | [2022/33] | Type: | A1 Application with search report | No.: | EP4291651 | Date: | 20.12.2023 | Language: | EN | The application published by WIPO in one of the EPO official languages on 18.08.2022 takes the place of the publication of the European patent application. | [2023/51] | Search report(s) | International search report - published on: | US | 18.08.2022 | (Supplementary) European search report - dispatched on: | EP | 03.06.2025 | Classification | IPC: | C12N15/11, A61K48/00 | [2023/51] | CPC: |
A01K67/0275 (EP,IL);
C12N15/113 (EP,IL,KR,US);
A61K31/7088 (KR);
A61P9/04 (KR);
A61P9/06 (KR);
A61P9/10 (US);
C07K14/4703 (EP,IL);
C07K14/70582 (US);
C07K16/2881 (US);
C12N15/115 (US);
C12N9/22 (US);
A01K2207/15 (EP,IL);
A01K2217/072 (EP,IL);
A01K2227/105 (EP,IL);
A01K2267/0375 (EP,IL);
C12N2310/14 (EP,IL,KR,US);
C12N2310/314 (US);
C12N2310/315 (EP,IL,KR,US);
C12N2310/321 (US);
C12N2310/322 (EP,IL,KR,US);
C12N2310/3231 (EP,IL,KR);
C12N2310/3341 (EP,IL,KR,US);
C12N2310/341 (EP,IL,KR);
C12N2310/345 (EP,IL,KR);
| C-Set: |
C12N2310/322, C12N2310/3525 (EP)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2023/51] | Extension states | BA | 16.08.2023 | ME | 16.08.2023 | Title | German: | VERBINDUNGEN UND VERFAHREN ZUR REDUZIERUNG DER PLN-EXPRESSION | [2023/51] | English: | COMPOUNDS AND METHODS FOR REDUCING PLN EXPRESSION | [2023/51] | French: | COMPOSÉS ET PROCÉDÉS POUR RÉDUIRE L'EXPRESSION DE PLN | [2023/51] | Entry into regional phase | 16.08.2023 | National basic fee paid | 16.08.2023 | Search fee paid | 16.08.2023 | Designation fee(s) paid | 16.08.2023 | Examination fee paid | Examination procedure | 16.08.2023 | Examination requested [2023/51] | 19.01.2026 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time | 13.03.2026 | Amendment by applicant (claims and/or description) | 13.03.2026 | Date on which the examining division has become responsible | Request for further processing for: | The application is deemed to be withdrawn due to failure to indicate the wish to proceed further with the application | 13.03.2026 | Request for further processing filed | 13.03.2026 | Full payment received (date of receipt of payment) | The application is deemed to be withdrawn due to failure to reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report/Supplementary European search report | 13.03.2026 | Request for further processing filed | 13.03.2026 | Full payment received (date of receipt of payment) | Fees paid | Renewal fee | 03.01.2024 | Renewal fee patent year 03 | 28.02.2025 | Renewal fee patent year 04 | 02.03.2026 | Renewal fee patent year 05 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [XI] WO0116312 (RIBOZYME PHARM INC et al.) [X] 1-4,6 * page 74 - page 82; claims 82-84,88,90-92,113-116; tables 24-30; sequences 909,2297,1073,2612 *[I] 1-17 | [A] US2003050259 (BLATT LAWRENCE et al.) [A] 1-17 | [X] WO2018154439 (CRISPR THERAPEUTICS AG et al.) [X] 1-2,4,6,13-14 * claim 71; sequence 14299 * | [XI] US2010298697 (THAKKER DEEPAK RAMESH et al.) [X] 1-4,6-7,9,11 * pages 15,20 - paragraph 20; table 3; sequences 282,295 *[I] 1-17 | [I] MORIHARA HIROFUMI ET AL: "Phospholamban Inhibition by a Single Dose of Locked Nucleic Acid Antisense Oligonucleotide Improves Cardiac Contractility in Pressure Overload-Induced Systolic Dysfunction in Mice", JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS., vol. 22, no. 3, 2 November 2016 (2016-11-02), US, pages 273 - 282, XP093218980, ISSN: 1074-2484, Retrieved from the Internet DOI: http://dx.doi.org/10.1177/1074248416676392 | [I] SPAETER D ET AL: "Phospholamban antisense oligonucleotides drive the reversal of cardiac dysfunction and multiple heart failure parameters during murine dilated cardiomyopathy", 31 August 2019 (2019-08-31), XP093218982, Retrieved from the Internet | International search | [A] US2017204407 (GILBERT LUKE A et al.) [A] 1-3, 7-9, 108 * entire document * | [A] US2005288244 (MANOHARAN MUTHIAH et al.) [A] 1-3, 7-9, 108 * entire document * | [A] US2011078833 (WU WEI et al.) [A] 1-3, 7-9, 108 * entire document * |